Springer, Private Bag 65901, Mairangi Bay 0754, Auckland, New Zealand.
Drugs. 2017 Dec;77(18):2063-2070. doi: 10.1007/s40265-017-0840-z.
Abemaciclib (Verzenio™) is an orally administered inhibitor of cyclin-dependent kinases 4 and 6 that is being developed by Eli Lilly and Company. Abemaciclib has been approved in the USA for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer, in combination with fulvestrant in women with disease progression following endocrine therapy, and as monotherapy in adult patients with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting. In addition, abemaciclib is in various stages of development internationally for a variety of cancers. This article summarizes the milestones in the development of abemaciclib leading to its first approval for the treatment of patients with HR-positive, HER2-negative advanced or metastatic breast cancer.
阿贝西利（Verzenio™）是一种由礼来公司开发的、口服的细胞周期蛋白依赖性激酶 4 和 6 抑制剂。阿贝西利已在美国获得批准，用于治疗激素受体（HR）阳性、人表皮生长因子受体 2（HER2）阴性的晚期或转移性乳腺癌，与氟维司群联合用于内分泌治疗后疾病进展的女性，以及用于内分泌治疗后疾病进展且先前在转移性环境中接受过化疗的成年患者的单药治疗。此外，阿贝西利在国际上也处于各种癌症的不同开发阶段。本文总结了阿贝西利开发过程中的重要里程碑，最终使其获得批准，用于治疗 HR 阳性、HER2 阴性的晚期或转移性乳腺癌患者。
